Global Access to Advanced Therapies: Bridging the Gap in Middle and Low-Income Countries

Dr. Rajangam is responsible for leading the development and regulatory strategy to rapidly advance Senti Bio’s off-the-shelf CAR-NK cell oncology programs into and through clinical development. Dr. Rajangam served in leadership roles at various biotech companies, most recently Nkarta Therapeutics where, as chief medical officer, she was responsible for clinical development of CAR-NK cell therapies for oncology.

Amicia Elliott is a scientist and product leader working at the intersection of life sciences, technology development, and entrepreneurship. At Form Bio, Dr. Elliott leads product strategy for biological computing, workflow development, user experience for scientific platform features, and laboratory validation of machine learning models. Prior to this role, she was a Research Fellow at the NIH in behavioral neuroscience and high-resolution optical imaging. Dr. Elliott’s scientific expertise is in genetics, light microscopy and optical engineering, and computer vision machine learning. She has experience in academia and government leading science policy efforts in biomedical research and ethical AI, and is a 2x Founder and Scientific Advisor. Dr. Elliott completed a postdoctoral fellowship at the NIH/NIGMS, received her Ph.D. from Vanderbilt University in the Department of Molecular Physiology and Biophysics, and earned her B.S. in Genetics at Purdue University.

Jeff is a seasoned CEO with a proven track record at profitably growing emerging companies and business divisions. He has raised over $15M in seed capital from angel investors to start four different companies which he then led to becoming profitable or acquired. Jeff got his start in Cell therapy as the Chief Operating Officer of Progenitor Cell Therapy (PCT) where he supported over 25 clinical trials in the Cell and Gene Therapy field. These trials ranged from Phase I to Phase III pivotal trials.

Kevin’s combined experiences in academia and real-world implementation give him a unique perspective for solving global health problems. He has built a reputation as a thought leader on the societal implications of emerging technologies and am known for his ability to build meaningful partnerships, foster collaboration, and communicate with diverse audiences. He has written extensively for both peer-reviewed publications and general audience publications and has given many presentations on genomics, bioethics, and healthcare policy. Notably, he is currently co-authoring a white paper on the infrastructure development needed to improve access to gene therapies in India and Africa.

Shardha is a consultant at Citeline (formerly Pharma Intelligence) who specializes in cell and gene therapy, working with Biotech and Pharmaceutical companies conducting competitive research and strategic market analysis. Shardha is also active in thought leadership creation, having published articles for Citeline's In Vivo publication, as well as quarterly reports on the Gene, Cell and RNA landscape published as part of a continuing partnership with the American Society of Gene and Cell Therapy.